Why you should avoid microdosing weight-loss drugs | Max Healthcare’s Dr Mithal explains

GLP-1 microdosing is a viral trend of people experimenting with smaller-than-recommended doses to lose weight. Dr Ambrish Mithal, the group chairman and head of endocrinology and diabetology at Max Healthcare, says that a lower dose does not automatically mean safer treatmentA year after GLP-1 drugs entered the Indian market, a concerning new trend has emerged – microdosing semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).